The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health

Contraception

Volumn 79, Issue 3, 2009, Pages 167-177

  Guilbert, Edith R ^a   Brown, Jacques P ^b   Kaunitz, Andrew M ^c   Wagner, Marie Soleil ^a   Bérubé, Jocelyn ^d   Charbonneau, Louise ^a   Francoeur, Diane ^e   Gilbert, Andrée ^a   Gilbert, François ^f   Roy, Geneviève ^a   Senikas, Vyta ^g   Jacob, Robert ^a   Morin, Réal ^a  

^a INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^b Association of Rheumatologists of Quebec   (Canada)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d Federation of General Practitioners of Quebec   (Canada)

^e Association of Obstetricians and Gynaecologists of Quebec   (Canada)

^f Association of Endocrinologists of Quebec   (Canada)

^g The Society of Obstetricians and Gynaecologists of Canada   (Canada)

Author keywords

Bone mineral density; Contraception; Depot medroxyprogesterone acetate; Quebec, Canada; Skeletal health

Indexed keywords

CALCIUM; ESTROGEN; GESTAGEN; GLUCOCORTICOID; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; VITAMIN D;

BONE DENSITY; BREAST FEEDING; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOMETRIOSIS; FRACTURE; FRAGILITY FRACTURE; HORMONAL CONTRACEPTION; HUMAN; MEDICAL SOCIETY; OSTEOPENIA; OSTEOPOROSIS; PHOTON ABSORPTIOMETRY; PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; REPRODUCTIVE HEALTH; REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT INDICATION; UNWANTED PREGNANCY; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

BONE DENSITY; CANADA; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; FEMALE; FRACTURES, BONE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; OSTEOPOROSIS; PREGNANCY; PREGNANCY RATE;

EID: 58749104910     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2008.10.016     Document Type: Review

References (103)

1. Kaunitz A.M. Depo-Provera's black box: time to reconsider?. Contraception 72 (2005) 165-167
2. Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 169 (2003) 207-208
3. Black A., Francoeur D., Rowe T., et al. Canadian contraception consensus. J Obstet Gynaecol Can 26 (2004) 347-436
4. http://www.fda.gov/bbs/topics/NEWS/NEW00303.html Accessed 12-02-2008
5. http://205.193.93.51/NocWeb/viewnoce.jsp?noc=erii Accessed 12-09-2008
6. Hatcher R.A., Trussell J., Stewart F., et al. Contraceptive Technology. 18th rev ed. (2004), Ardent Media Inc., New York
7. Société des obstétriciens et gynécologues du Canada, National Quantitative Landscape Study. 2006 Contraception Awareness Project (CAP) Canadian Contraceptive Study. Unpublished manuscript. 2006.
8. http://www40.statcan.ca/l01/cst01/health41a.htm Accessed 12-02-2008
9. http://www.statcan.ca/english/clf/query.html?qm=1&charset=iso-8859-1 &la=en&qt=Table+106-9002&ct=1234532358 Accessed 12-02-2008
10. Letourneau N.L., Stewart M.J., and Barnfather A.K. Adolescent mothers: support needs, resources, and support-education interventions. J Adolesc Health 35 (2004) 509-525
11. Unicef. A league table of teenage birth in rich nations. Innocenti report card (2001), UNICEF Innocenti Centre, Florence No. 3
12. Gosselin C., Lanctôt N., and Paquette D. La grossesse à l'adolescence: conséquences de la parentalité, prévalence, caractéristiques associées à la maternité et programmes de prévention en milieu scolaire. In: Vitaro F., and Gagnon C. (Eds). Prévention des problèmes d'adaptation chez les enfants et les adolescents, tome II-Les problèmes externalisés (2000), Les presses de l'Université du Québec, Sainte-Foy 463-492
13. Fisher W., Boroditsky R., and Bridges M.L. The 1998 Canadian Contraception Study. Can J Hum Sex 8 (1999) 161-220
14. Fisher W., Boroditsky R., and Morris B. The 2002 Canadian Contraception Study: part 1. J Obstet Gynaecol Can 26 (2004) 580-590
15. Lefebvre G., Pinsonneault O., Antao V., et al. Primary dysmenorrhea consensus guideline. J Obstet Gynaecol Can 27 (2005) 1117-1146
16. Jarrell J.F., Vilos G.A., Allaire C., et al. Consensus guidelines for the management of chronic pelvic pain. J Obstet Gynaecol Can 27 (2005) 781-826
17. Kennedy S., Bergqvist A., Chapron C., et al. ESHRE Guideline for the diagnosis and treatment of endometriosis. Hum Reprod 20 (2005) 2698-2704
18. American College of Obstetricians and Gynecologists. Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 107 (2006) 1453-1472 [ACOG Practice Bulletin No. 73]
19. Kaunitz A.M. Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol 170 5 Pt 2 (1994) 1543-1549
20. Croxatto H.B. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception 65 (2002) 21-27
21. Kahn H.S., Curtis K.M., and Marchbanks P.A. Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk. Diabetes Care 26 (2003) 216-225
22. Westhoff C. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. J Reprod Med 41 Suppl (1996) 401-406
23. Garza-Flores J., De la Cruz D.L., Valles D.B., et al. Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception 44 (1991) 61-71
24. Enk L., Landgren B.M., Lindberg U.B., Silfverstolpe G., and Crona N. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 24 (1992) 85-89
25. Graff-Iversen S., and Tonstad S. Use of progestogen-only contraceptives/medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian survey. Contraception 66 (2002) 7-13
26. Sorensen M.B., Collins P., Ong P.J., et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 106 (2002) 1646-1651
27. Kaunitz A.M. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 107 (2003) e67-e68
28. World Health Organization. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 57 (1998) 315-324
29. World Health Organization. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis (1994), World Health Organization, Geneva WHO Technical Report Series 843
30. Looker A.C., Orwoll E.S., Johnston C.C., et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12 (1997) 1761-1768
31. Khan A.A., Bachrach L., Brown J.P., et al. Standards and guidelines for performing central dual x-ray densitometry in premenopausal women, men, and children from the Canadian Panel of the International Society of Clinical Densitometry. J Clin Densitom 7 (2004) 51-63
32. Vendittoli P.A., Major D., Simpson A., Jean S., and Brown J.P. Descriptive study of osteoporotic fractures and hip fracture risk evaluation of subjects with past minor fractures. World Congress on Osteoporosis, Chicago, Illinois, USA, June 15-18. Osteoporos Int 11 suppl (2000) S109 [Abstract 197]
33. Tenenhouse A., Joseph L., Kreiger N., et al. Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 11 (2000) 897-904
34. Brown J.P., and Josse R.G. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167 Suppl (2002) S1-S34
35. Bessette L., Ste-Marie L.G., Jean S., et al. Recognizing osteoporosis and its consequences in Quebec (ROCQ): background, rationale, and methods of an anti-fracture patient health-management programme. Contemp Clin Trials 29 (2008) 194-210
36. Keen R.W., Hart D.J., Arden N.K., Doyle D.V., and Spector T.D. Family history of appendicular fracture and risk of osteoporosis: a population-based study. Osteoporos Int 10 (1999) 161-166
37. Rubin L.A., Hawker G.A., Peltekova V.D., Fielding L.J., Ridout R., and Cole D.E. Determinants of peak bone mass: clinical and genetic analyses in a young female Canadian cohort. J Bone Miner Res 14 (1999) 633-643
38. Adachi J.D., Olszynski W.P., Hanley D.A., et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 29 (2000) 228-251
39. Cadarette S.M., McIsaac W.J., Hawker G.A., et al. The validity of decision rules for selecting women with primary osteoporosis for bone mineral density testing. Osteoporos Int 15 (2004) 361-366
40. Marshall D., Johnell O., and Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312 (1996) 1254-1259
41. Van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., and Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15 (2000) 993-1000
42. http://www.nice.org.uk/guidance/index.jsp?action=article&o=40235 Accessed 12-02-2008
43. Karlsson M.K., Ahlborg H.G., and Karlsson C. Maternity and bone mineral density. Acta Orthop 76 (2005) 2-13
44. Kalkwarf H.J. Lactation and maternal bone health. Adv Exp Med Biol 554 (2004) 101-114
45. Kalkwarf H.J., and Specker B.L. Bone mineral changes during pregnancy and lactation. Endocrine 17 (2002) 49-53
46. Speroff L., Glass R.H., and Kase N.G. Clinical gynecologic endocrinology and infertility. 6th ed. (1999), Lippincott Williams and Wilkins, Baltimore (MD)
47. Karlsson M.K., Ahlborg H.G., and Karlsson C. Female reproductive history and the skeleton - a review. BJOG 112 (2005) 851-856
48. Ensom M.H., Liu P.Y., and Stephenson M.D. Effect of pregnancy on bone mineral density in healthy women. Obstet Gynecol Surv 57 (2002) 99-111
49. Karlsson C., Obrant K.J., and Karlsson M. Pregnancy and lactation confer reversible bone loss in humans. Osteoporos Int 12 (2001) 828-834
50. More C., Bettembuk P., Bhattoa H.P., and Balogh A. The effects of pregnancy and lactation on bone mineral density. Osteoporos Int 12 (2001) 732-737
51. Black A.J., Topping J., Durham B., Farquharson R.G., and Fraser W.D. A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J Bone Miner Res 15 (2000) 557-563
52. Naylor K.E., Iqbal P., Fledelius C., Fraser R.B., and Eastell R. The effect of pregnancy on bone density and bone turnover. J Bone Miner Res 15 (2000) 129-137
53. Honda A., Kurabayashi T., Yahata T., Tomita M., Takakuwa K., and Tanaka K. Lumbar bone mineral density changes during pregnancy and lactation. Int J Gynaecol Obstet 63 (1998) 253-258
54. Ritchie L.D., Fung E.B., Halloran B.P., et al. A longitudinal study of calcium homeostasis during human pregnancy and lactation and after resumption of menses. Am J Clin Nutr 67 (1998) 693-701
55. Drinkwater B.L., and Chesnut III C.H. Bone density changes during pregnancy and lactation in active women: a longitudinal study. Bone Miner 14 (1991) 153-160
56. Polatti F., Capuzzo E., Viazzo F., Colleoni R., and Klersy C. Bone mineral changes during and after lactation. Obstet Gynecol 94 (1999) 52-56
57. Kolthoff N., Eiken P., Kristensen B., and Nielsen S.P. Bone mineral changes during pregnancy and lactation: a longitudinal cohort study. Clin Sci (Lond) 94 (1998) 405-412
58. Krebs N.F., Reidinger C.J., Robertson A.D., and Brenner M. Bone mineral density changes during lactation: maternal, dietary, and biochemical correlates. Am J Clin Nutr 65 (1997) 1738-1746
59. Affinito P., Tommaselli G.A., di Carlo C., Guida F., and Nappi C. Changes in bone mineral density and calcium metabolism in breastfeeding women: a one year follow-up study. J Clin Endocrinol Metab 81 (1996) 2314-2318
60. Lopez J.M., Gonzalez G., Reyes V., Campino C., and Diaz S. Bone turnover and density in healthy women during breastfeeding and after weaning. Osteoporos Int 6 (1996) 153-159
61. Sowers M., Corton G., Shapiro B., et al. Changes in bone density with lactation. JAMA 269 (1993) 3130-3135
62. Hayslip C.C., Klein T.A., Wray H.L., and Duncan W.E. The effects of lactation on bone mineral content in healthy postpartum women. Obstet Gynecol 73 (1989) 588-592
63. Laskey M.A., and Prentice A. Bone mineral changes during and after lactation. Obstet Gynecol 94 (1999) 608-615
64. Bezerra F.F., Mendonca L.M., Lobato E.C., O'Brien K.O., and Donangelo C.M. Bone mass is recovered from lactation to postweaning in adolescent mothers with low calcium intakes. Am J Clin Nutr 80 (2004) 1322-1326
65. Chantry C.J., Auinger P., and Byrd R.S. Lactation among adolescent mothers and subsequent bone mineral density. Arch Pediatr Adolesc Med 158 (2004) 650-656
66. Cure-Cure C., Cure-Ramirez P., Teran E., and Lopez-Jaramillo P. Bone-mass peak in multiparity and reduced risk of bone-fractures in menopause. Int J Gynaecol Obstet 76 (2002) 285-291
67. Nguyen T.V., Jones G., Sambrook P.N., White C.P., Kelly P.J., and Eisman J.A. Effects of estrogen exposure and reproductive factors on bone mineral density and osteoporotic fractures. J Clin Endocrinol Metab 80 (1995) 2709-2714
68. Tuppurainen M., Kroger H., Saarikoski S., Honkanen R., and Alhava E. The effect of gynecological risk factors on lumbar and femoral bone mineral density in peri- and postmenopausal women. Maturitas 21 (1995) 137-145
69. Hillier T.A., Rizzo J.H., Pedula K.L., et al. Nulliparity and fracture risk in older women: the study of osteoporotic fractures. J Bone Miner Res 18 (2003) 893-899
70. Kojima N., Douchi T., Kosha S., and Nagata Y. Cross-sectional study of the effects of parturition and lactation on bone mineral density later in life. Maturitas 41 (2002) 203-209
71. Johansson C., Mellstrom D., and Milsom I. Reproductive factors as predictors of bone density and fractures in women at the age of 70. Maturitas 17 (1993) 39-50
72. Dursun N., Akin S., Dursun E., Sade I., and Korkusuz F. Influence of duration of total breast-feeding on bone mineral density in a Turkish population: does the priority of risk factors differ from society to society?. Osteoporos Int 17 (2006) 651-655
73. Gur A., Cevik R., Nas K., Sarac A.J., Ataoglu S., Karakoc M., et al. The influence of duration of breastfeeding on bone mass in postmenopausal women of different age groups. Int J Clin Pract 57 (2003) 82-86
74. Sinigaglia L., Varenna M., Binelli L., Gallazzi M., Calori G., and Ranza R. Effect of lactation on postmenopausal bone mineral density of the lumbar spine. J Reprod Med 41 (1996) 439-443
75. O'Neill T.W., Silman A.J., Naves D.M., Cooper C., Kanis J., and Felsenberg D. Influence of hormonal and reproductive factors on the risk of vertebral deformity in European women. European Vertebral Osteoporosis Study Group. Osteoporos Int 7 (1997) 72-78
76. Cummings S.R., Nevitt M.C., Browner W.S., et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332 (1995) 767-773
77. Alderman B.W., Weiss N.S., Daling J.R., Ure C.L., and Ballard J.H. Reproductive history and postmenopausal risk of hip and forearm fracture. Am J Epidemiol 124 (1986) 262-267
78. Johnell O., Gullberg B., Kanis J.A., et al. Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res 10 (1995) 1802-1815
79. Petersen H.C., Jeune B., Vaupel J.W., and Christensen K. Reproduction life history and hip fractures. Ann Epidemiol 12 (2002) 257-263
80. Michaelsson K., Baron J.A., Farahmand B.Y., and Ljunghall S. Influence of parity and lactation on hip fracture risk. Am J Epidemiol 153 (2001) 1166-1172
81. Clark M.K., Sowers M., Levy B.T., and Tenhundfeld P. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril 75 (2001) 871-877
82. Mishell Jr. D.R. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 41 Suppl (1996) 381-390
83. Gracia C.R., Sammel M.D., Freeman E.W., et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. Menopause 12 (2005) 128-135
84. Curtis K.M., and Martins S.L. Progestogen-only contraception and bone mineral density: a systematic review. Contraception 73 (2006) 470-487
85. Kaunitz A.M., Miller P.D., Rice V.M., Ross D., and McClung M.R. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 74 (2006) 90-99
86. Shaarawy M., El-Mallah S.Y., Seoudi S., Hassan M., and Mohsen I.A. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Contraception 74 (2006) 297-302
87. Cromer B.A., Bonny A.E., Stager M., et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil Steril 90 (2008) 2060-2067
88. Rosenberg L., Zhang Y., Constant D., et al. Bone status after cessation of use of injectable progestin contraceptives. Contraception 76 (2007) 425-431
89. Kaunitz A.M., Arias R., and McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 77 (2008) 67-76
90. Scholes D., LaCroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 13 (2002) 581-587
91. Orr-Walker B.J., Evans M.C., Ames R.W., Clearwater J.M., Cundy T., and Reid I.R. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 49 (1998) 615-618
92. Cundy T., Cornish J., Roberts H., and Reid I.R. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am J Obstet Gynecol 186 (2002) 978-983
93. Scholes D., LaCroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 159 (2005) 139-144
94. Cundy T., Ames R., Horne A., et al. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab 88 (2003) 78-81
95. Cromer B.A., Lazebnik R., Rome E., et al. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol 192 (2005) 42-47
96. Schlaff W.D., Carson S.A., Luciano A., Ross D., and Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 85 (2006) 314-325
97. Crosignani P.G., Luciano A., Ray A., and Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 21 (2006) 248-256
98. http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html Accessed 12-02-2008
99. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2005/depo-pr overa_2_hpc-cps-eng.php Accessed 04-12-2008
100. World Health Organization. Department of Reproductive Health and Research. WHO statement on hormonal contraception and bone health. Weekly Epidemiological record 35 (2005) 302-304
101. The National Collaborating Centre for Women's and Children's Health. Long-acting reversible contraception-Clinical Guideline 30 (2005), National Institute for Health and Clinical Excellence, London, United Kingdom 1-176
102. Cromer B.A., Scholes D., Berenson A., Cundy T., Clark M.K., and Kaunitz A.M. Depot medroxyprogesterone acetate and bone mineral density in adolescents-the black box warning: a position paper of the Society for Adolescent Medicine. J Adolesc Health 39 (2006) 296-301
103. Black A and Ad Hoc DMPA Committee of the Society of Obstetricians and Gynaecologists of Canada. Canadian contraception consensus-update on depot medroxyprogesterone acetate (DMPA. J Obstet Gynaecol Can 28 (2006) 305-313